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StreptozotocinPGC-1α is a transcriptional coactivator that controls energy homeostasis through regulation of glucose andoxidative
metabolism. BothPGC-1α expressionandoxidative capacity aredecreased in skeletalmuscle of patients andanimals
undergoing atrophy, suggesting that PGC-1α participates in the regulation ofmusclemass. PGC-1α gene expression
is controlled by calcium- and cAMP-sensitive pathways. However, the mechanism regulating PGC-1α in skeletal
muscle during atrophy remains unclear. Therefore, we examined themechanism responsible for decreased PGC-1α
expression using a rodent streptozotocin (STZ) model of chronic diabetes and atrophy. After 21 days, the levels of
PGC-1α protein andmRNAwere decreased.We examined the activation state of CREB, a potent activator of PGC-1α
transcription, and found that phospho-CREBwas paradoxically high inmuscle of STZ-rats, suggesting that the cAMP
pathway was not involved in PGC-1α regulation. In contrast, expression of calcineurin (Cn), a calcium-dependent
phosphatase, was suppressed in the samemuscles. PGC-1α expression is regulated by two Cn substrates, MEF2 and
NFATc. Therefore, we examinedMEF2 andNFATc activity inmuscles from STZ-rats. Target genesMRF4 andMCIP1.4
mRNAs were both signiﬁcantly reduced, consistent with reduced Cn signaling. Moreover, levels of MRF4, MCIP1.4,
and PGC-1α were also decreased in muscles of CnAα−/− and CnAβ−/− mice without diabetes indicating that
decreased Cn signaling, rather than changes in other calcium- or cAMP-sensitive pathways, were responsible for
decreased PGC-1α expression. These ﬁndings demonstrate that Cn activity is a major determinant of PGC-1α
expression in skeletal muscle during diabetes and possibly other conditions associated with loss of muscle mass.druff Memorial Building, 1639
. Tel.: +1 404 727 3934.
B.V.Published by Elsevier B.V.1. Introduction
Diabetes mellitus (DM) is an epidemic public health issue that
threatens the health and quality of life of people globally. DM can
result from insulin deﬁciency or resistance and is characterized by a
variety of metabolic disturbances including reduced cellular glucose
uptake, decreased fatty acid oxidation, and dysfunctional mitochon-
dria [1]. Skeletal muscle is a major site of insulin action and loss of
insulin signaling induces muscle atrophy, which leads to reduced
functional capacity and muscle weakness [1].
PGC-1α is a transcriptional coactivator that participates in the
regulation of skeletal muscle metabolism, particularly energy homeosta-
sis. It controls glucose transport and is necessary for mitochondrial
biogenesis and the maintenance of the oxidative phenotype of muscle
ﬁbers [2]. Skeletalmuscles ofmice transgenically overexpressing PGC-1α
have an increasedproportion of oxidativeﬁbers [3]. Recently, PGC-1αhasbeen implicated in the regulation of muscle mass and protein turnover.
Glycolytic ﬁbers express a lower level of PGC-1α and they exhibit a
greater degree of atrophy than oxidative ﬁbers in disease or systemic
models of muscle atrophy [4–6]. In general, PGC-1α expression is lower
in skeletal muscles undergoing atrophy, including those of Type II
DM patients [7–9]. The mechanism of the atrophy-related reduction of
PGC-1α in skeletal muscle is unknown.
Given the multi-faceted role of PGC-1α in energy metabolism, it is
not surprising that the control of its transcription is complex. Several
signaling pathways (e.g., MAP kinase, cAMP/PKA) induce PGC-1α
transcription by phosphorylating Ser133 in the cAMP response
element binding protein (CREB). Activated CREB forms a complex
with other proteins (e.g., p300, CREB Binding Protein or CBP) which
then bind to a cAMP response element located in the promoter region
of the PGC-1α gene [10,11]. Thus, a reduction in CREB activity could be
responsible for the reduction in PGC-1α during muscle atrophy.
Another pathway known to regulate PGC-1α involves the calcium-
dependent phosphatase calcineurin (Cn). Two downstream sub-
strates of calcineurin, NFATc and MEF2 have been proposed to work
in concert to increase the transcription of prototypical type I oxidative
muscle ﬁber genes, including PGC-1α [12]. Importantly, transgenic
Table 1
Overall body weight and muscle weights are reduced in 21-day STZ-treated rats.
CTL STZ
Glucose (mg/dl) 153±14.7 427±29.8*
Initial body weight (g) 157±5.3 154±5.9
Final body weight (g) 346±11.7 254±8.4*
Gastrocnemius weight (g) 2.2±0.08 1.3±.011*
Epitrochlearis weight (mg) 57.1±3.4 39.1±4.7*
21-day DM rats presented with hyperglycemia and signiﬁcantly smaller body and wet
skeletal muscle (gastrocnemius and epitrochlearis) weights compared to controls.
Mean±SEM, n=8, *Pb0.05.
Fig. 1. The rate of protein degradation and ubiquitin expression are increased in 21-day
STZ-treated rat muscle. (A) Protein degradation was measured in isolated mixed-ﬁber
epitrochlearis skeletal muscles. Muscles from control and 21-day STZ-treated rats were
incubated in Krebs–Ringer bicarbonate buffer with cycloheximide to inhibit protein
synthesis. Free tyrosine released into the media was measured ﬂuorometrically after
being converted to a nitrosonapthol derivative. (B) Ubiquitin C (rUbC) mRNA in the
gastrocnemius muscles was measured by real-time RT-PCR. Data were normalized to
18S RNA and expressed as mean fold increase over control. Data are expressed as the
mean±SEM; n=7/group, Pb0.05.
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overexpression by inducing a switching from glycolytic to oxidative
ﬁbers [3,13,14]. Thus, a second possible mechanism that could lead to
down-regulation of PGC-1α expression is a reduction in Cn signaling.
In the present study, we found that chronic DM induced by a low-
dose of streptozotocin increased skeletal muscle protein degradation
and decreased PGC-1α expression. This led us to examine the possible
mechanisms that could be responsible for reducing PGC-1α tran-
scription. Our results demonstrate that insulin deﬁciency leads to
suppression of Cn signaling and a resulting decrease in PGC-1α
transcription.
2. Methods
2.1. Materials
Streptozotocin (STZ) was purchased from Sigma-Aldrich (St. Louis,
MO). The following commercially available antibodies were used: anti-
actin (Sigma-Aldrich), anti-Akt and anti-phospho(S473) Akt (Cell
Signaling: Danvers, MA), anti-calcineurin pan A (Chemicon: Billerica,
MA), anti-CREB and anti-phospho(S133) CREB (Cell Signaling), anti-
glycogen synthase and anti-phospho(S641) glycogen synthase (Cell
Signaling), anti-GSK-3β and anti-phospho(S9) GSK-3β (Cell Signaling),
anti-NFATc1 (Abcam: Cambridge, MA), anti-MEF2 (Santa Cruz: Santa
Cruz, CA), anti-PGC-1 (Calbiochem: SanDiego, CA), andHRP-anti-rabbit
IgG (Amersham:Piscataway,NJ). The followingprimerswerepurchased
from Invitrogen (Carlsbad, CA) for real-time RT-PCR:
DHPRα1s primers FWD 5′-TTTCCCACAGGCCGTGCTGCTGCTCTTCA-
3′ and REV 5′-CATGTAGAAGCTGATGAA-3′ [15,16], MCIP1.4 primers
previously published [18], MRF4 primers previously published [19], and
PGC-1α primers previously published [20], rUbC primers previously
published [15].
2.2. Animals
2.2.1. STZ-DM rats
All studies were approved by the Emory University Institutional
Animal Care and Use Committee. Male Sprague–Dawley rats weighing
∼150 g were anesthetized using isoﬂourane and given a single tail-
vein injection of 60 mg/kg body weight of streptozotocin (STZ)
prepared fresh in 0.1 M sodium citrate buffer (pH4.0); control rats
were injected with the vehicle alone. Chronically diabetic animals
were fed the standard diet ad libitum for 21 days. At the time of
sacriﬁce, animals were anesthetized and the gastrocnemius muscles
were immediately frozen in liquid nitrogen and then stored at−80 °C.
Arterial blood was collected for glucose measurements.
2.2.2. STZ-DM transgenic mice
Transgenic mice expressing a NFAT-luciferase (NFAT-luc) reporter
gene in all tissues were created by Dr. J. Molkentin (Cincinnati Children's
Hospital, Cincinnati, OH) [17,18]. Mice weighing 25–30 g were given an
interperitoneal injection of either 55 mg/kg body weight STZ in 0.1 M
sodiumcitrate buffer (pH. 4.0) or sodiumcitrate buffer alonedaily for four
days. Blood glucose levels were monitored for 1 week following the last
injection of STZ. Mice with blood glucose levels more than 200 mg/dl
were considered diabetic. Diabetic mice were fed standard chow and
water ad libitum for 21 days and blood glucose levels were monitored
weekly. At the time of sacriﬁce, blood was obtained to measure glucose
prior to harvesting the gastrocnemius muscle. Blood glucose levels were
similar to those for STZ-treated rats (data not shown). Dissectedmuscles
were immediately frozen in liquid nitrogen and stored at−80 °C.
2.2.3. Calcineurin knockout mice
Mice lacking the gene for theα isoform of the CnA catalytic subunit
were created by Dr. J. Seidman (Howard Hughes Medical Institute,
Harvard Medical School, Boston, MA) [19]. Mice lacking the gene forthe β isoform of the CnA catalytic subunit were created by Dr. J.
Molkentin (Cincinnati Children's Hospital, Cincinnati, OH) [17,18].2.3. Western blot analysis
Muscle samples were homogenized in 20 μl/mg of lysis buffer. Two
different lysis buffers were used. A hypotonic buffer consisting of 50 mM
Tris (pH7.5), 1 mM EDTA, 1 mM EGTA, 0.5 mM DTT, 0.1% NP-40, and
completemini protease inhibitor cocktail tablets (Roche, Indianapolis, IN)
was used for analysis of Cn, NFAT, MEF2, and PGC-1α. The samples were
subjected to three freeze/thaw cycles using liquid nitrogen and a 37 °C
water bath. The homogenates were centrifuged and the supernatant was
used for analysis. A buffer consisting of 50 mMHEPES (pH 7.4), 137 mM
NaCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM Na pyrophosphate, 10 mM Na
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10 μg/ml aprotinin, 10 μg/ml leupeptin, and 10 mM benzamidine was
used for analysis of AKT, CREB, GSK-3β, and glycogen synthase (GS).
Supernatant protein concentrations were measured using a BioRad DC
Protein Assay Kit (BioRad, Hercules, CA). Protein samples (50 μg) were
separated by SDS–PAGE, transferred to nitrocellulose membranes and
blocked in Tris-buffered saline (pH7.5) containing 5% non-fat milk and
0.1% Tween-20(Sigma, St. Louis, MO). Blots were incubatedwith primary
antibodies (see Section 2.1) and detected using chemiluminescence
technology. Equal protein loading and transfer were conﬁrmed by
Ponceau S Red staining of the membranes.
2.4. Real-time RT-PCR
Rat or mouse gastrocnemius muscle RNA was isolated using Trizol
Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's
instructions, treated with DNase and reverse transcribed using M-MLV
reverse transcriptase and random hexamer primers. Real-time PCRwas
performed using a BioRad iCycler with target-speciﬁc primers and iQ
SYBR Green (BioRad, Hercules, CA); the 18S rRNA was used as a
normalization control. The data were analyzed for fold change (ΔΔCt)
using the iCycler software.
2.5. Endogenous NFATc activity assay
Luciferase activity in the gastrocnemius muscles of control and STZ-
treated NFATc-luc mice was measured using a commercial kit (Promega,
Madison, WI). Tissue samples were homogenized in 20 μl/mg passive
lysis buffer and particulate matter removed by centrifugation. Total
protein content of the supernatant was measured using a BioRad DCFig. 3. CREB signaling is abnormal in 21-daySTZ-treated ratmuscle. (A) Thephosphorylation
(i.e., activation) status of CREB in gastrocnemius muscles of control and 21-day STZ-treated
rats was examined by Western blot analysis using antibodies that detect phospho-Ser133
and total CREB. Data are expressed as the mean ratio of phosphorylated protein to total
protein±SEM. Equal protein loading and transfer were conﬁrmed by Ponceau S staining.
n=6/group, *Pb0.05. (B) Toevaluate CREB function, the amounts ofDHPRα1s, a gene target
ofCREB,weremeasured ingastrocnemiusmusclesby real timeRT-PCR.Dataareexpressedas
the mean±SEM; n=8/group, *Pb0.05.
Fig. 2. PGC-1α expression is decreased in 21-day STZ-treated rat muscle. (A) PGC-1α
protein was evaluated by Western blot analysis. Equal protein loading and transfer was
conﬁrmed by Ponceau S staining. n=9/group, *Pb0.05. (B) PGC-1α mRNA in
gastrocnemius muscle was measured by real time RT-PCR, normalized to 18S RNA,
and expressed as mean fold change relative to control±SEM; n=7/group, *Pb0.05.Protein Assay Kit (Hercules, CA), and all lysates were diluted to a
concentration of 1 μg/μl with passive lysis buffer. Luciferase assay reagent
(50 μl) was added to 10 μl of supernatant and luminescence was
measured for 10 seconds using a luminometer (Turner Biosystems,
Sunnyvale, CA).Fig. 4. Cn catalytic A subunit protein is decreased in 21-day STZ-treated rat muscle. The
levels of Cn A subunit (CnA) protein in gastrocnemius muscles of control and 21-day
STZ-treated rats were measured by Western blot analysis using a pan antibody that
recognized all CnA isoforms. Equal protein loading and transfer were conﬁrmed by
Ponceau S staining. Data are expressed as the mean±SEM; n=12/group, *Pb0.05.
Fig. 5. NFATc activity is decreased in 21-day STZ-treated ratmuscle. Changes in Cn activity
are reﬂected in the activity of the transcription factor NFATc. (A) The amount of mRNA
encoding the NFATc target MCIP1.4 in gastrocnemius muscles was measured using real
time RT-PCR. Values were normalized to 18S RNA and expressed as mean fold change
relative to control±SEM; n=8/group, *Pb0.05. (B) The levels of NFATc1 proteins were
evaluated by Western blot analysis. n=10/group, P=0.14. (C) Transgenic mice
expressing a luciferase reporter gene under the control of a NFAT-responsive promoter
were injected with STZ (an intraperitoneal injection of STZ (55 mg/kg) daily for 4 days).
After 21 days, muscle NFATc activity was evaluated by measuring luciferase activity in
lysates prepared from gastrocnemius muscles. Data are expressed as mean luminescence
units±SEM; n=3/group, *Pb0.05.
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The rate of total protein degradation was measured in isolated,
mixed-ﬁber epitrochlearis muscles as described [20]. Brieﬂy, freshly
isolated muscles were incubated for 2 h at 37 °C in Krebs–Ringer
bicarbonate buffer containing cyclohexamide to inhibit protein
synthesis. Free tyrosine released into the media by proteolysis was
measured ﬂuorometrically [21]. The rate of tyrosine release was
calculated as the nmol tyrosine released/mg wet muscle weight/
hour.
3. Results
3.1. Rats treated with streptozotocin experience skeletal muscle atrophy
due to increased protein degradation
Streptozotocin (STZ) was administered to rats to induce Type I DM
(i.e., insulin deﬁciency and hyperglycemia) and cachexia. After 21 days,
STZ rats were hyperglycemic with signiﬁcantly smaller body and wet
muscle weights than controls (Table 1). To conﬁrm that increased
muscle protein turnover contributed to the lower muscle mass, total
protein degradation was measured in isolated epitrochlearis muscles.
The epitrochlearis is a small,ﬂat,mixed-ﬁber-typemuscle located in the
fore-limb. The size of the muscle allows for extended incubation times
after dissection without induction of necrosis. Additionally, protein
degradation rates measured in the epitrochlearis are comparable to
those of the perfused hind limb [22]. Therefore, the ratemeasured in the
epitrochlearis is representative of whole body protein breakdown. The
proteolytic rate was increased in epitrochlearis muscles of STZ-treated
rats (Fig. 1A). A second independent measure of protein degradation,
expression of rat ubiquitin (UbC) mRNA, was also increased in
gastrocnemius muscle from STZ-treated rats versus controls (Fig. 1B).
3.2. PGC-1α expression is decreased in muscle from STZ-treated rats
Expression of the PGC-1α transcriptional co-activator has been
reported to bedownregulated in skeletalmuscle of humanswith insulin
resistance or Type II DM [8]. To determine whether PGC-1α is similarly
regulated in skeletal muscle of rats with chronic diabetes mellitus, we
evaluated PGC-1α protein and found it was decreased in the
gastrocnemius muscle of STZ-treated rats (Fig. 2A). The decrement in
PGC-1α protein appears to result from a pre-translational mechanism
because PGC-1αmRNA was also signiﬁcantly decreased in STZ-treated
rat muscle (Fig. 2B).
3.3. Decreased PGC-1α transcription is not due to decreased CREB
activity
One of the major signaling pathways that regulates PGC-1α
transcription involves the cAMP regulatory element binding protein
(CREB) via a CREB response element in the cofactor's promoter [11].
CREB is activatedbyphosphorylation of Ser 133byvarious Ca2+-sensing
and stress pathways including CaMKII, PKA, and ERK, thus making it
relevant in the context of reduced insulin-signaling [23]. To determine if
the reduction in PGC-1α transcription could be attributed to attenuated
CREB activity, we evaluated the amounts of CREB phospho-
Ser133 relative to total CREB protein. In contrast to the reduction of
PGC-1α, the amount of activated CREB wasmarkedly increased ∼8-fold
in STZ-treated rat muscle compared to controls (Fig. 3A). This
ﬁnding suggests that CREB function may be abnormal in the muscle of
STZ-treated rats and led us to evaluate the expression of a known CREB
target. The dihydropyridine receptor (DHPR) α1s subunit is expressed
exclusively in skeletal muscle, and its transcription is regulated by
CREB [24]. The level of DHPRα1s mRNAwas decreased in muscles from
STZ-treated rats (Fig. 3B).3.4. Calcineurin signaling is down-regulated in muscle from STZ-treated
rat
The calcium-dependent calcineurin (Cn) signaling pathway has also
been implicated in regulating PGC-1α transcription [25], prompting us
to investigate its role in regulating PGC-1α in our 21-day STZ-treated
rats. The amount of Cn catalytic A subunit (CnA) was decreased in
muscles from STZ-treated rats (Fig. 4). One of the best characterized
substrates of Cn is the NFATc transcription factor family. To determine
if NFATc activity was reduced, we measured the amount of mRNA
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MCIP1.4 is an NFATc responsive gene that has been used previously as
a surrogate reporter for Cn activity in skeletal muscle [26,27]. MCIP1.4
expression was decreased in gastrocnemius of STZ rats (Fig. 5A). To
determine whether the reduction in NFATc activity was a result of a
change in NFAT protein, the amount of NFATc1 protein was measuredFig. 7. MEF2 activity is decreased in 21-day STZ-treated rat muscle. (A) The amount of
mRNA encoding the MEF2 target MRF4 in gastrocnemius muscles was measured using real
timeRT-PCR,normalized to18SRNAandexpressedasmean fold change relative to control±
SEM. n=6/group, *Pb0.05. (B)MEF2A protein in gastrocnemiusmuscles of control and 21-
day STZ-treated rats was evaluated by Western blot analysis. Equal protein loading and
transfer were conﬁrmed by Ponceau S staining. n=8/group, P=0.74.since it is the major subclass of NFATc in muscle [28]. NFATc1 protein
expressionwas not signiﬁcantly changed in STZ ratmuscles (Fig. 5B). As
a way of conﬁrming that STZ-induced, chronic diabetes mellitus
attenuated NFATc activity in muscle, we compared luciferase activity
in the gastrocnemiusmuscle of control and STZ-treatedmice expressing
a NFATc responsive luciferase transgene in all tissues. Luciferase activity
was decreased in STZ-treated mice (Fig. 5C).
The activities of NFATc proteins can be regulated by either Cn or
glycogen synthase kinase-3β (GSK-3β) which phosphorylates and
inactivates the transcription factors [29]. In response to insulin, GSK-3β
is inactivated by AKT-mediated phosphorylation [30]. To exclude the
possibility that DM activated GSK-3β, we examined the phosphorylation
status of GSK-3β Ser-9. There was no difference in the level of
phosphorylated enzymeor enzymeexpression in STZ-treated and control
rat muscles (Fig. 6A). To conﬁrm that GSK-3β activity was unchanged,
we measured the levels of glycogen synthase (GS) phosphorylation atFig. 6. GSK-3β signaling is unchanged in 21-day STZ-treated rat muscle. (A) The
phosphorylation (i.e., inactivation) of GSK-3β on Ser-9 in gastrocnemius muscles was
examined by Western blot analysis using antibodies that detect phospho-S9 and total GSK-
3β. Data are expressed as the mean ratio of phosphorylated protein to total protein±SEM.
n=8/group, P=0.31. (B) The phosphorylation of glycogen synthase on Ser-641 also was
examined as a downstream target of GSK-3β activity by Western blot analysis using
antibodies that detect total and phospho-Ser-641 glycogen synthase. Data are expressed as
the mean ratio of phosphorylated protein to total protein±SEM. n=8/group, P=0.69.
(C)Westernblot analysis of Akt phosphorylationwasperformedusing antibodies that detect
total and phospho-Ser-473 Akt. Data are expressed as the mean ratio of phosphorylated
protein to total protein±SEM: Pb0.05. For each experiment, equal protein loading and
transfer were conﬁrmed by Ponceau S staining. n=7/group.
Fig. 8. MEF2 and NFATc signaling and PGC-1α mRNA are decreased in muscles of
CnAα−/− and CnAβ−/− mice. MRF4, MCIP1.4, and PGC-1α mRNAs in the gastrocne-
mius muscle of CnAα−/− and CnAβ−/− mice were measured by real-time RT-PCR,
normalized to 18S RNA and expressed as mean fold change relative to control±SEM;
n≥3/group, *Pb0.05.
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either the phosphorylation status or total protein expression between
STZ-treated versus control rat muscles (Fig. 6B). We also analyzed
the phosphorylation status of Ser-473 in Akt and found that it was
increased slightly but signiﬁcantly in STZ-treated rat muscle (Fig. 6C).
Together, these results indicate that GSK-3β signaling was unchanged in
STZ-treated animals.
MEF2 is another transcription factor that can regulate PGC-1α
expression and Cn has been shown to affect its activity. To evaluate
MEF2 activity, the amount ofmyogenic regulatory factor 4 (MRF4)mRNA
was measured because MEF2 is its primary regulator in differentiated
muscle cells [31,32]. In STZ-treated rat muscle, MRF4 mRNA was
decreased relative to control rat muscle (Fig. 7A). This response was not
due to a change in the amount of MEF2 protein (Fig. 7B).
3.5. Loss of calcineurin signaling results in decreased PGC-1α
transcription in skeletal muscle
To directly examine the relationship between Cn signaling
and PGC-1α expression, the level of PGC-1α mRNA was measuredFig. 9. Decreased Cn signaling downregulates PGC-1α during chronic diabetes mellitus. F
associated calcium signaling. Two parallel calcium-dependent pathways involving calcium-
primary pathway that regulates NFATc. Since both NFATc and MEF2 activities are attenuated
propose that reduced Cn signaling is predominantly responsible for the decreased level of PGC
associated with oxidative metabolism in skeletal muscle are likely to be affected. Suppre
perpetuate the decrease in muscle functional capacity and mass that accompanies diabetesin gastrocnemius muscles of CnAα−/− and CnAβ−/− mice. PGC-1α
expression was drastically reduced in both CnA−/− strains. Moreover,
NFAT activity, as measured by MCIP1.4 expression, was signiﬁcantly
decreased when either CnA subunit was absent (Fig. 8). MRF4
expression, a measure of MEF2 activity, was also signiﬁcantly
decreased in CnAβ−/− mice and tended to be lower in CnAα−/−
mice (Fig. 8).
4. Discussion
PGC-1α is a coactivator protein that participates in the transcrip-
tional regulation of a variety of genes involved in energy metabolism,
including the glucose transporter 4 (GLUT4) and mitochondrial
biogenesis [2,33–36]. Hyperglycemia in Type II DM patients has
been attributed, in part, to decreased expression of PGC-1α [8,37].
Other complications of Type I and Type II DM in experimental animals
include skeletal muscle atrophy and PGC-1α has been linked to the
regulation of skeletal muscle protein turnover (i.e., muscle mass) and
ﬁber type [5,20,38]. Furthermore, atrophy occurs preferentially in
muscles comprised predominantly of type II glycolytic ﬁbers during
DM and other systemic disease states are also associated with loss of
muscle oxidative capacity [5,39]. This preferential atrophy could be
linked to the reduction in PGC-1α expression since the cofactor helps
to maintain the type I oxidative ﬁber phenotype in muscle [3].
In the present studies, the levels of PGC-1α protein and mRNA
in skeletal muscle were decreased in a model of chronic (21-day)
STZ-induced DM. To elucidate the mechanism regulating PGC-1α
expression in this system, we ﬁrst tested whether CREB-mediated
signaling was altered because CREB is a potent regulator of PGC-1α
expression [40]. Paradoxically, the activation state of CREB was
increased in skeletal muscle of 21-day STZ-treated rats. This led us to
examine a relevant downstream target of CREB, DHPRα1s. DHPRα1s
forms the L-type calciumchannel in the T-tubules and is a voltage sensor
of excitation–contraction (EC) coupling [41]. A recent report demon-
strated that knockdown of DHPRα1s results in the induction of muscle
atrophy [41]. In our study, DHPRα1s mRNA was decreased in muscles
from STZ-treated rats, a ﬁnding that is suggests that CREB-mediatedunctional capacity and muscle mass are regulated by contractile and activity and the
calmodulin kinase (CaMK) and calcineurin (Cn) can regulate MEF2 whereas Cn is the
during chronic diabetes mellitus as well as in both CnAα and CnAβ knockout mice, we
-1α expression. Consequently, mitochondrial biogenesis and the expression of proteins
ssion of Cn/NFATc/MEF2 signaling and subsequent downregulation of PGC-1α may
mellitus.
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CREB tomediate its activity, including p300 or CBP [10]. One or more of
these interacting proteins could be altered in skeletal muscle of STZ-
treated rats, which would result in dysfunctional CREB signaling and
decreased expression of downstream targets like DHPRa1s and PGC-1a.
The Cn/NFATc/MEF2 signaling pathway has been linked to the
maintenance of overall muscle mass. Cn activity, which is induced by
exercise or other stimuli that raise intracellular calcium, activates two
relevant downstream substrates, MEF2 and NFATc [42,43]. These
transcription factors regulate the expression of genes involved in
maintenance of overall muscle mass and the oxidative ﬁber
phenotype, including PGC-1α (Fig. 9) [42].
Since NFATc can be inactivated by phosphorylation of the kinase
GSK-3β, we examined Akt/GSK-3β signaling and found no evidence
that the pathway was activated in STZ-treated rats. Although
phosphorylation of Akt on Ser-473 was slightly elevated, the increase
did not seem to be physiologically relevant with regard to GSK-3β
signaling or suppression of protein degradation. Tong et al. [44]
reported similar paradoxical ﬁndings involving increased atrophy-
related responses despite augmented levels of phosphorylated Akt.
In muscles of STZ-treated rats, extensive evidence was found to
indicate that the decrease in CnA protein was the primary cause of the
reduction in overall pathway signaling. The role of Cn in the regulation
of PGC-1α gene expression was conﬁrmed when PGC-1α mRNA was
found to be lower in the muscles of CnAα−/− and CnAβ−/− mice.
Together, these results suggest three possible interpretations. First,
CnAα and CnAβ may have overlapping actions with regard to
activating NFATc and MEF2. Second, CnAα and CnAβ may exhibit
selectivity for either MEF2 or NFATc and inactivation of either
transcription factor is sufﬁcient to reduce PGC-1α expression
regardless of the activation status of the other protein. Lastly, MEF2
and NFAT could act cooperatively to regulate PGC-1α and inactivation
of either protein is sufﬁcient to affect cofactor expression. Further
studies will be necessary to delineate the intricacies of this
mechanism in the context of diabetes. The reduction in PGC-1α
expression may contribute to the chronic muscle atrophy induced by
DM. This cofactor has been proposed to protect against atrophy
through several different mechanisms. First, PGC-1α can antagonize
FoxO-dependent transcription of AT-1 [5]. Decreased PGC-1α protein
could perpetuate atrophy through the loss of FoxO inhibition and
subsequent upregulation of AT-1. In light of the fact that AT-1 mRNA
was not increased in 21-day STZ-treated rat muscle, it would seem
other mechanisms are responsible for sustaining muscle wasting
(data not shown). Second, the loss of PGC-1α could affect oxidative
metabolism as PGC-1α is necessary to maintain the oxidative muscle
ﬁber phenotype and helps to protect muscle cells against increased
oxidative stress [3,45]. In other studies, we found that chronic DM
reduced the proportion of oxidative MHC Type I ﬁbers relative to
glycolytic MHC II ﬁbers in soleus muscles (TKR et al., manuscript
submitted). Therefore, the loss of PGC-1α may contribute to the
progression of muscle atrophy by increasing the number of glycolytic
ﬁbers, which are more prone to undergo atrophy induced by systemic
pathologic conditions [6,46]. This could account for the perpetuation
of atrophy over long periods of time.
In summary, our studies have shown that DM suppresses the Cn/
NFATc/MEF2 signaling pathway and that this may perpetuate muscle
wasting by downregulating PGC-1α expression. Recent reports
indicate that increasing muscle contractile activity through resistance
exercise may help to attenuate the muscle atrophy process [47,48].
Our ﬁndings suggest that contractile activity may attenuate chronic
wasting by increasing the activation state of Cn or by activating
alternative calcium signaling pathways that bypass Cn, such as
calmodulin-dependent kinase (CaMK) (Fig. 9). Lastly, our results
provide a possible explanation for the myopathy that frequently
develops in transplant recipients who receive Cn inhibitors as part of
their immunosuppressive regimen and suggests that these drugs maymake the post-surgical rehabilitation of these patients more difﬁcult
[49]. A better understanding of the role of Cn inmuscle atrophywill be
important for improving rehabilitation of patients suffering from
systemic disease or receiving immunosuppressive therapies.
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